+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019

  • ID: 4758535
  • Drug Pipelines
  • 129 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • BeyondSpring Inc
  • Bolder Biotechnology Inc
  • Lupin Ltd
  • Nohla Therapeutics Inc
  • Pfizer Inc
  • Richter Gedeon Nyrt
  • MORE
Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights:

This latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 5, 8, 6 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • BeyondSpring Inc
  • Bolder Biotechnology Inc
  • Lupin Ltd
  • Nohla Therapeutics Inc
  • Pfizer Inc
  • Richter Gedeon Nyrt
  • MORE
Introduction

Chemotherapy Induced Neutropenia - Overview

Chemotherapy Induced Neutropenia - Therapeutics Development

Chemotherapy Induced Neutropenia - Therapeutics Assessment

Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development

Chemotherapy Induced Neutropenia - Drug Profiles

Chemotherapy Induced Neutropenia - Dormant Projects

Chemotherapy Induced Neutropenia - Discontinued Products

Chemotherapy Induced Neutropenia - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Number of Products under Development by Universities/Institutes, H1 2019

Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019 (Contd..1), H1 2019

Products under Development by Companies, H1 2019 (Contd..2), H1 2019

Products under Development by Universities/Institutes, H1 2019

Number of Products by Stage and Target, H1 2019

Number of Products by Stage and Mechanism of Action, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Enzychem Lifesciences Corp, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc., H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Profarma, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Tanvex BioPharma Inc, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H1 2019

Chemotherapy Induced Neutropenia - Pipeline by Valenta Pharmaceuticals, H1 2019

Chemotherapy Induced Neutropenia - Dormant Projects, H1 2019

Chemotherapy Induced Neutropenia - Dormant Projects, H1 2019 (Contd..1), H1 2019

Chemotherapy Induced Neutropenia - Discontinued Products, H1 2019

List of Figures

Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2019

Number of Products under Development by Companies, H1 2019

Number of Products by Targets, H1 2019

Number of Products by Stage and Targets, H1 2019

Number of Products by Top 10 Mechanism of Actions, H1 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • BeyondSpring Inc
  • Biocon Ltd
  • Bolder Biotechnology Inc
  • Cellerant Therapeutics Inc
  • Chong Kun Dang Pharmaceutical Corp
  • Dr. Reddy's Laboratories Ltd
  • Enzychem Lifesciences Corp
  • Gene Techno Science Co Ltd
  • Generon (Shanghai) Corp Ltd
  • GlycoMimetics Inc
  • Hanmi Pharmaceuticals Co Ltd
  • Lupin Ltd
  • Mycenax Biotech Inc
  • Nohla Therapeutics Inc
  • Pangen Biotech Inc.
  • Pfizer Inc
  • Profarma
  • Prolong Pharmaceuticals LLC
  • Richter Gedeon Nyrt
  • Sandoz International GmbH
  • Tanvex BioPharma Inc
  • USV Pvt Ltd
  • Valenta Pharmaceuticals
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4758535
Adroll
adroll